Peanut Allergy clinical trials

Explore recruiting peanut allergy clinical trials.

Recruiting peanut allergy studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Peanut Allergy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy

Spain, France, Netherlands, Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of immunotherapy in peanut-allergic patients.

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX)

Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE)

Netherlands, Ireland, Germany, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Peanut Allergy trials by city

Peanut Allergy in Toronto Peanut Allergy in Vancouver Peanut Allergy in Montreal Peanut Allergy in Calgary Peanut Allergy in Edmonton Peanut Allergy in Ottawa Peanut Allergy in Winnipeg Peanut Allergy in Quebec City Peanut Allergy in Hamilton Peanut Allergy in Kitchener Peanut Allergy in London Peanut Allergy in Halifax Peanut Allergy in New York Peanut Allergy in Los Angeles Peanut Allergy in Chicago Peanut Allergy in Houston

Peanut Allergy clinical trials

Recruiting peanut allergy studies right now

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Oral Immunotherapy for Peanut Allergic Patients

Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

Immune-supportive Diet and Gut Permeability in Allergic Children

UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies

TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Single Ascending and Multiple Ascending Dose Study of LCA-0061

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

Also recruiting in Europe

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy

A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of immunotherapy in peanut-allergic patients.

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX)

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE)

Peanut Allergy trials by city

Other conditions